IL216159A - Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication - Google Patents

Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication

Info

Publication number
IL216159A
IL216159A IL216159A IL21615911A IL216159A IL 216159 A IL216159 A IL 216159A IL 216159 A IL216159 A IL 216159A IL 21615911 A IL21615911 A IL 21615911A IL 216159 A IL216159 A IL 216159A
Authority
IL
Israel
Prior art keywords
sedation
medicaments
preparation
delivery device
same
Prior art date
Application number
IL216159A
Other languages
English (en)
Hebrew (he)
Other versions
IL216159A0 (en
Original Assignee
Recro Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43085620&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL216159(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recro Pharma Inc filed Critical Recro Pharma Inc
Publication of IL216159A0 publication Critical patent/IL216159A0/en
Publication of IL216159A publication Critical patent/IL216159A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/06—Head
    • A61M2210/0625—Mouth

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL216159A 2009-05-15 2011-11-06 Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication IL216159A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17873009P 2009-05-15 2009-05-15
PCT/US2010/035136 WO2010132882A2 (en) 2009-05-15 2010-05-17 Sublingual dexmedetomidine compositions and methods of use thereof

Publications (2)

Publication Number Publication Date
IL216159A0 IL216159A0 (en) 2012-01-31
IL216159A true IL216159A (en) 2015-10-29

Family

ID=43085620

Family Applications (1)

Application Number Title Priority Date Filing Date
IL216159A IL216159A (en) 2009-05-15 2011-11-06 Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication

Country Status (21)

Country Link
US (1) US20110021588A1 (enExample)
EP (2) EP2429521B1 (enExample)
JP (2) JP6172938B2 (enExample)
KR (1) KR101859486B1 (enExample)
CN (2) CN106511273A (enExample)
AU (1) AU2010248776B2 (enExample)
BR (1) BRPI1010567A2 (enExample)
CA (1) CA2762107A1 (enExample)
CL (1) CL2011002858A1 (enExample)
CO (1) CO6460767A2 (enExample)
CR (1) CR20110596A (enExample)
DO (1) DOP2011000354A (enExample)
EC (1) ECSP11011459A (enExample)
HN (1) HN2011003011A (enExample)
IL (1) IL216159A (enExample)
MX (1) MX2011011950A (enExample)
NZ (1) NZ596976A (enExample)
PE (1) PE20120713A1 (enExample)
RU (1) RU2572692C2 (enExample)
SG (1) SG175979A1 (enExample)
WO (1) WO2010132882A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130096170A1 (en) 2011-10-14 2013-04-18 Hospira, Inc. Methods of treating pediatric patients using dexmedetomidine
JP6268100B2 (ja) * 2011-12-11 2018-01-24 レクロ・ファーマ，インコーポレーテッド 鼻腔内デクスメデトミジン組成物およびその使用方法
US8242158B1 (en) 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
CA2865593A1 (en) * 2012-02-27 2013-09-06 Eye Therapies Llc Compositions and methods for the treatment of migraine
CN104797252B (zh) * 2012-10-15 2016-09-21 奥赖恩公司 减轻噪音厌恶的兽医方法
EP2792352A1 (en) * 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
US20150273215A1 (en) * 2014-03-26 2015-10-01 Pacesetter, Inc. Systems and methods for assessment of pain and other parameters during trial neurostimulation
CN106456561B (zh) 2013-10-07 2020-02-28 帝国制药美国公司 使用右旋美托咪啶经皮组合物治疗注意力缺陷多动症、焦虑症和失眠症的方法和组合物
KR20180095732A (ko) * 2013-10-07 2018-08-27 테이코쿠 팔마 유에스에이, 인코포레이티드 비진정량의 덱스메데토미딘의 경피 전달을 위한 방법 및 조성물
CA2924231C (en) 2013-10-07 2018-04-03 Teikoku Pharma Usa, Inc. Dexmedetomidine transdermal delivery devices and methods for using the same
RU2557882C1 (ru) * 2014-07-08 2015-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Астраханская государственная медицинская академия" Министерства здравоохранения Российской Федерации (ГБОУ ВПО АГМА Минздрава России) Способ проведения премедикации при плановом хирургическом лечении
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
HUE055565T2 (hu) * 2016-12-13 2021-11-29 Orion Corp Dexmedetomidin vagy medetomidin alkalmazása a szeparációs szorongás kezelésében kedvtelésbõl tartott állatoknál
EP3562486B1 (en) 2016-12-31 2024-03-13 Bioxcel Therapeutics, Inc. Use of sublingual dexmedetomidine for the treatment of agitation
EP3813802B1 (en) 2018-06-27 2024-10-23 Bioxcel Therapeutics, Inc. Film formulations containing dexmedetomidine and methods of producing them
WO2020176807A1 (en) 2019-02-27 2020-09-03 Vanderbilt University Methods of treating trigeminal nerve pain
CN112138250B (zh) * 2019-06-28 2023-04-14 四川普锐特药业有限公司 保持给药均一度的药物流体分配器及右美托咪定鼻喷器
AU2020316013A1 (en) * 2019-07-19 2022-02-17 Arx, Llc Non-sedating dexmedetomidine treatment regimens
CN118948739A (zh) * 2020-06-08 2024-11-15 四川普锐特药业有限公司 右美托咪定滴鼻剂或鼻喷剂在助眠药物制备中的应用
US20220031664A1 (en) * 2020-07-28 2022-02-03 Melt Pharmaceuticals, Inc. Pharmaceutical compositions comprising antiemetics and alpha-2-adrenergic receptor agonists and methods of using the same for anesthesiological applications
EP4583871A1 (en) * 2022-09-11 2025-07-16 BioXcel Therapeutics, Inc. Methods for treating agitation in community settings
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens
CN118542852B (zh) * 2024-07-30 2024-10-01 山东则正医药技术有限公司 包含经口给药的右美托咪定舌下膜组合物及其制备方法和应用

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5217718A (en) * 1989-08-18 1993-06-08 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
US5124157A (en) * 1989-08-18 1992-06-23 Cygnus Therapeutic Systems Method and device for administering dexmedetomidine transdermally
FI894911A0 (fi) * 1989-10-17 1989-10-17 Farmos Oy En terapeutiskt vaerdefull foerening.
DE10299002I1 (de) * 1990-12-05 2012-07-05 Gen Hospital Corp Verwendung von No zur Behandlung oder Praevention der Bronchokonstriktion
GB9111732D0 (en) * 1991-05-31 1991-07-24 Orion Yhtymae Oy The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs
US5571840A (en) * 1993-06-22 1996-11-05 The Regents Of The University Of Michigan Method for treating central nervous system ischemia
US5713907A (en) * 1995-07-20 1998-02-03 Endotex Interventional Systems, Inc. Apparatus and method for dilating a lumen and for inserting an intraluminal graft
GB9520150D0 (en) 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
US20050281752A1 (en) * 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077227A1 (en) * 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US6716867B1 (en) 1998-04-01 2004-04-06 Orion Corporation Use of dexmedetomidine for ICU sedation
AR015744A1 (es) * 1998-04-01 2001-05-16 Orion Corp Uso de dexmedetomidina para sedacion en terapia intensiva
US7001609B1 (en) * 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
HUP0103543A2 (hu) * 1998-10-02 2002-01-28 3M Innovative Properties Company Nyálkahártyán megtapadó hatóanyag bejuttató rendszerek és ezek alkalmazása állatok kezelésére
GB9913677D0 (en) * 1999-06-11 1999-08-11 Imperial College Formulation
AUPR184500A0 (en) * 2000-12-01 2001-01-04 Drug Delivery Solutions Pty Ltd Dispensing device
WO2002089794A1 (en) * 2001-05-07 2002-11-14 Universite Catholique De Louvain Method for treating neuropathic pain and pharmaceutical preparation therefor
WO2002094238A1 (en) * 2001-05-24 2002-11-28 Alexza Molecular Delivery Corporation Delivery of anti-migraine compounds through an inhalation route
FR2834212B1 (fr) * 2001-12-27 2004-07-09 Besins Int Belgique Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20090117054A1 (en) * 2005-03-29 2009-05-07 University Of Kentucky Research Foundation Sublingual spray for the treatment of pain
US8486972B2 (en) * 2006-01-25 2013-07-16 Insys Therapeutics, Inc. Sublingual fentanyl spray
ES2624577T3 (es) * 2006-02-13 2017-07-17 Orient Pharma (Samoa) Co. Ltd. Formulación líquida que comprende un agonista de los receptores alfa-2 (por ejemplo, clonidina) y oxibutinina (agente antimuscarínico) para el tratamiento de sialorrea
US20080021074A1 (en) * 2006-06-29 2008-01-24 Questcor Pharmaceuticals, Inc. Pharmaceutical Compositions and Related Methods of Treatment
CN101057830A (zh) * 2007-05-10 2007-10-24 北京天川军威医药技术开发有限公司 盐酸纳洛酮舌下喷雾给药系统或组合物及其制备方法

Also Published As

Publication number Publication date
CO6460767A2 (es) 2012-06-15
EP2429521A2 (en) 2012-03-21
MX2011011950A (es) 2012-02-21
HN2011003011A (es) 2014-12-01
DOP2011000354A (es) 2012-07-15
CL2011002858A1 (es) 2012-06-22
JP2012526854A (ja) 2012-11-01
CN106511273A (zh) 2017-03-22
WO2010132882A3 (en) 2011-03-31
EP3305281A1 (en) 2018-04-11
IL216159A0 (en) 2012-01-31
KR20120008058A (ko) 2012-01-25
US20110021588A1 (en) 2011-01-27
CR20110596A (es) 2012-03-26
RU2572692C2 (ru) 2016-01-20
CA2762107A1 (en) 2010-11-18
EP2429521B1 (en) 2017-10-18
ECSP11011459A (es) 2012-01-31
EP2429521A4 (en) 2013-08-21
AU2010248776A1 (en) 2012-01-12
JP6172938B2 (ja) 2017-08-02
JP2016029055A (ja) 2016-03-03
RU2011151059A (ru) 2013-06-20
PE20120713A1 (es) 2012-07-08
KR101859486B1 (ko) 2018-06-28
NZ596976A (en) 2014-05-30
WO2010132882A2 (en) 2010-11-18
SG175979A1 (en) 2011-12-29
CN102639131A (zh) 2012-08-15
BRPI1010567A2 (pt) 2016-03-15
WO2010132882A8 (en) 2011-12-29
AU2010248776B2 (en) 2013-06-06

Similar Documents

Publication Publication Date Title
IL216159A (en) Oral trans-mucosal dexamedomidine preparations, a delivery device that includes them and their use in the preparation of pain-relieving pain medication
IL244974A0 (en) Preparations in flat form containing buprenorphine and naloxone, formulations in flat form containing them, and their use in the preparation of drugs for the treatment of narcotic dependence
IL268756B (en) Piperazine-2,5-dione derivatives, pharmaceutical preparations containing them and their use for the preparation of medicines
IL234166B (en) Isoindoline compounds, a pharmaceutical composition containing it and its use in the preparation of a medicine
IL202379A (en) Benzoxaborols, their pharmaceutical preparations and their use in the preparation of bacteria to inhibit the growth of germs
IL206952A (en) History of Aminodia Hydrothiazine, medicinal preparations containing them, and their use in the preparation of medicines
IL271132A (en) New preparation and dosage
IL218169A (en) Quinazoline compounds and their pharmaceutical compositions containing them for use in therapy
IL212573A (en) Aryl Methyl Benzokinazulinone Compounds
PL2601962T3 (pl) Schemat dawkowania LAG-3 do stosowania w leczeniu raka
IL213019A (en) Derivatives 1-Azo-3-Terroyl-Azoline, Pharmaceutical Preparations Containing and Using Them
ZA201206062B (en) Aminotetraline derivatives,pharmaceutical compositions containing them,and their use in therapy
IL221940A (en) Small anti-infective compounds, pharmaceutical preparations containing them and their use in the preparation of drugs for the treatment of bacterial infections
ZA201003899B (en) Novel dosage and formulation
IL193762A (en) The effective compounds in inhibiting dgat1-related disorders, their medicinal products and their use in the preparation of drugs
EP2361081A4 (en) MULTI-PARALLEL INTRA-ORAL DOSAGE FORM AND USE THEREOF
GB201119686D0 (en) Pharmaceutical compositions and related methods of delivery
IL211842A (en) Antibodies or fragments of their human tgfbrii, pharmacological preparations containing them and their use in the preparation of a drug for inhibiting anogenesis
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
IL211120A (en) Compound, tetracycline converted at position 7c with fluorine, a pharmaceutical preparation containing it and its use in the preparation of drugs for the treatment of bacteria-caused infection
IL218277B (en) Tetracycline compounds, pharmaceutical preparations containing them and their use for the preparation of medicines for the treatment and prevention of infection
EP2370068A4 (en) METHOD AND COMPOSITIONS FOR DELIVERING MEDICAMENTS TO THE LUNG
IL215840A (en) Arylsulfonamide compounds are converted into two positions 2 and 5, their pharmaceutical composition containing them and their use in the treatment of ccr3-related diseases
IL202307A (en) Multikinase inhibitors for use in the preparation of pharmaceuticals for the treatment of various cancers
IL207205A0 (en) Triazolopyridazines as par1 inhibitors, their preparation and use as medicaments

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed